Abstract
The phosphoinositide 3-kinase (PI3K)/AKT pathway plays an important role in cancer development and progression. Mammalian target of rapamycin (mTOR) is a downstream effector of this pathway and is responsible for various cellular functions including mRNA translation, cell cycle progression and cellular proliferation. Activation of the PI3K/AKT pathway plays an important role in normal and neoplastic T and B cell proliferation. Abnormal activation of this pathway is seen in various hematologic malignancies. This knowledge has lead to an interest in evaluating the use of mTOR inhibitors in hematologic malignancies. The prototype mTOR inhibitor is rapamycin. Three other drugs are being evaluated in clinical trials. This review focuses on the biologic function of the PI3K/AKT/mTOR pathway and the mTOR inhibitors that are in clinical development for treatment of hematological malignancies.
Keywords: Hematological Malignancies, mammalian target of rapamycin (mTOR), cell cycle progression, Human Cancer, cellular proliferation, rapamycin
Current Cancer Therapy Reviews
Title: Role of mTOR in Hematological Malignancies
Volume: 4 Issue: 3
Author(s): Uzma Athar and Ajeet Gajra
Affiliation:
Keywords: Hematological Malignancies, mammalian target of rapamycin (mTOR), cell cycle progression, Human Cancer, cellular proliferation, rapamycin
Abstract: The phosphoinositide 3-kinase (PI3K)/AKT pathway plays an important role in cancer development and progression. Mammalian target of rapamycin (mTOR) is a downstream effector of this pathway and is responsible for various cellular functions including mRNA translation, cell cycle progression and cellular proliferation. Activation of the PI3K/AKT pathway plays an important role in normal and neoplastic T and B cell proliferation. Abnormal activation of this pathway is seen in various hematologic malignancies. This knowledge has lead to an interest in evaluating the use of mTOR inhibitors in hematologic malignancies. The prototype mTOR inhibitor is rapamycin. Three other drugs are being evaluated in clinical trials. This review focuses on the biologic function of the PI3K/AKT/mTOR pathway and the mTOR inhibitors that are in clinical development for treatment of hematological malignancies.
Export Options
About this article
Cite this article as:
Athar Uzma and Gajra Ajeet, Role of mTOR in Hematological Malignancies, Current Cancer Therapy Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339408785294294
DOI https://dx.doi.org/10.2174/157339408785294294 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design Immunosuppressive Properties of Mesenchymal Stem Cells: Advances and Applications
Current Molecular Medicine Prospects of Embryonic Stem Cells in Treatment of Hematopoietic Disorders
Current Pharmaceutical Biotechnology Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21)
Current Protein & Peptide Science Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry Interleukin 2 in Cancer Therapy
Current Medicinal Chemistry Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design Withdrawal Notice: Electrophoresis as a Tool for Early Cancer Diagnosis
Anti-Cancer Agents in Medicinal Chemistry Novel Immunotherapeutic Strategies for Invasive Fungal Disease
Current Drug Targets - Cardiovascular & Hematological Disorders 2', 4'-dihydroxy-3, 4-methylenedioxychalcone Activate Mitochondrial Apoptosis of Ehrlich Ascites Carcinoma Cells
Current Drug Therapy Desferrioxamine as Immunomodulatory Agent During Microorganism Infection
Current Pharmaceutical Design In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy Exploitation of Apoptosis Pathways for Childhood Leukemia
Current Pediatric Reviews Meganucleases and Other Tools for Targeted Genome Engineering: Perspectives and Challenges for Gene Therapy
Current Gene Therapy Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Current Cancer Drug Targets Targeting MDM2 and MDMX in Retinoblastoma
Current Cancer Drug Targets Dendritic Cells and their Receptors in Antitumor Immune Response
Current Molecular Medicine Biosafety Considerations Using Gamma-Retroviral Vectors in Gene Therapy
Current Gene Therapy